βII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin

Hepatology

Volumn 61, Issue 2, 2015, Pages 598-612

  Zhi, Xiuling ^a,b   Lin, Ling ^a   Yang, Shaoxian ^a   Bhuvaneshwar, Krithika ^a   Wang, Hongkun ^a   Gusev, Yuriy ^a   Lee, Mi Hye ^a   Kallakury, Bhaskar ^a   Shivapurkar, Narayan ^a   Cahn, Katherine ^a   Tian, Xuefei ^a   Marshall, John L ^a   Byers, Stephen W ^a   He, Aiwu R ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 SPECTRIN; BETA CATENIN; CLAUDIN 7; EPITHELIAL CELL ADHESION MOLECULE; KALLISTATIN; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PLASMA PROTEIN; SPECTRIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ACTIN BINDING PROTEIN; CADHERIN; CARRIER PROTEIN; CELL ADHESION MOLECULE; FODRIN; SERINE PROTEINASE INHIBITOR; TUMOR ANTIGEN; TUMOR-ASSOCIATED ANTIGEN GA733; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY; ANIMAL; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION; GENE SILENCING; LIVER NEOPLASMS; METABOLISM; MORTALITY; NUDE MOUSE; TUMOR RECURRENCE;

ANIMALS; ANTIGENS, NEOPLASM; BETA CATENIN; CADHERINS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL ADHESION MOLECULES; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; MICE, NUDE; MICROFILAMENT PROTEINS; NEOPLASM RECURRENCE, LOCAL; SERPINS; VIMENTIN; WNT PROTEINS;

EID: 84921506774     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27558     Document Type: Article

References (37)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-2128.
2. American Cancer Society. Cancer Facts & Figures 2013. Atlanta, GA: ACS.
3. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005;23:2892-2899.
4. Kong D, Li Y, Wang Z, Sarkar FH. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers (Basel) 2011;3:716-729.
5. Fuxe J, Vincent T, Garcia DHA. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle 2010;9:2363-2374.
6. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011;145:926-940.
7. Espinoza I, Pochampally R, Xing F, Watabe K, Miele L. Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Oncol Targets Ther 2013;6:1249-1259.
8. Merchant AA, Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010;16:3130-3140.
9. Xia H, Cheung WK, Ng SS, Jiang X, Jiang S, Sze J, et al. Loss of brain-enriched miR-124 microRNA enhances stem-like traits and invasiveness of glioma cells. J Biol Chem 2012;287:9962-9971.
10. Kalluri R, Weinberg RA The basics of epithelial-mesenchymal transition J Clin Invest 2009;119:1420-1428.
11. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-715.
12. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 2009;10:468-477.
13. Yuzugullu H, Benhaj K, Ozturk N, Senturk S, Celik E, Toylu A, et al. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer 2009;8:90.
14. Tang Y, Katuri V, Dillner A, Mishra B, Deng CX, Mishra L. Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice. Science 2003;299:574-577.
15. Thenappan A, Shukla V, Abdul KF, Li Y, Shetty K, Liu P, et al. Loss of transforming growth factor beta adaptor protein beta-2 spectrin leads to delayed liver regeneration in mice. Hepatology 2011;53:1641-1650.
16. Patel-Hett S, Wang H, Begonja AJ, Thon JN, Alden EC, Wandersee NJ, et al. The spectrin-based membrane skeleton stabilizes mouse megakaryocyte membrane systems and is essential for proplatelet and platelet formation. Blood 2011;118:1641-1652.
17. Lim JA, Baek HJ, Jang MS, Choi EK, Lee YM, Lee SJ, et al. Loss of beta2-spectrin prevents cardiomyocyte differentiation and heart development. Cardiovasc Res 2014;101:39-47.
18. Kitisin K, Ganesan N, Tang Y, Jogunoori W, Volpe EA, Kim SS, et al. Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene 2007;26:7103-7110.
19. Thenappan A, Li Y, Kitisin K, Rashid A, Shetty K, Johnson L, et al. Role of transforming growth factor beta signaling and expansion of progenitor cells in regenerating liver. Hepatology 2010;51:1373-1382.
20. Baek HJ, Kim SS, Da SF, Volpe EA, Evans S, Mishra B, et al. Inactivation of TGF-beta signaling in lung cancer results in increased CDK4 activity that can be rescued by ELF. Biochem Biophys Res Commun 2006;346:1150-1157.
21. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976;13:29-83.
22. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007;45:938-947.
23. Madhavan S, Gusev Y, Harris M, Tanenbaum DM, Gauba R, Bhuvaneshwar K, et al. G-DOC: a systems medicine platform for personalized oncology. Neoplasia 2011;13:771-783.
24. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 2007;67:10831-10839.
25. Chao J, Tillman DM, Wang MY, Margolius HS, Chao L. Identification of a new tissue-kallikrein-binding protein. Biochem J 1986;239:325-331.
26. + cells of normal and injured mouse liver. Development 2009;136:1951-1960.
27. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009;136:1012-1024.
28. Schmelzer E, Zhang L, Bruce A, Wauthier E, Ludlow J, Yao HL, et al. Human hepatic stem cells from fetal and postnatal donors. J Exp Med 2007;204:1973-1987.
29. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-890.
30. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006;172:973-981.
31. Katuri V, Tang Y, Li C, Jogunoori W, Deng CX, Rashid A, et al. Critical interactions between TGF-beta signaling/ELF, and E-cadherin/beta-catenin mediated tumor suppression. Oncogene 2006;25:1871-1886.
32. Clevers H Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-480.
33. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-850.
34. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000;10:185-200.
35. Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 2001;3:683-686.
36. Zhang B, Abreu JG, Zhou K, Chen Y, Hu Y, Zhou T, et al. Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family. Proc Natl Acad Sci U S A 2010;107:6900-6905.
37. Zhang J, Yang Z, Li P, Bledsoe G, Chao L, Chao J. Kallistatin antagonizes Wnt/beta-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6. Mol Cell Biochem 2013;379:295-301.